Diverticular Disease (DD) and Symprove study overview

In this double-blind, placebo-controlled trial 120 adults with moderate to severe diverticular disease (DD) were randomised to receive either Symprove or a matching placebo drink for three months.

The study concluded that Symprove had a significant benefit on

  • Reducing the frequency of constipation, diarrhoea, mucorrhea and back pain
  • Prevented an escalation in inflammatory activity in males
  • Was associated with fewer diverticulitis episodes in a subgroup of patients.

Faecal calprotectin levels were measured before and after treatment. Reductions in calprotectin levels (intestinal inflammation) were observed in the majority (75%) of male patients with DD. The decrease in intestinal inflammation was significantly greater than in the placebo group.

Reductions in calprotectin levels (intestinal inflammation) were observed in the majority (75%) of male patients with DD

‘These are exciting and significant results as up to now there has been no proven effective treatment for patients.’

Professor Ingvar Bjarnason, consultant gastroenterology and principal investigator of the study.

The independent study was carried out at Kings College Hospital London by Dr Savvas Papagrigoriadis and Professor Ingvar Bjarnason. The results of the study were presented at the leading world Gastroenterology congress, Digestive Disease Week, San Diego, in May 2016.